– custom synthesis
– formulation development
– analysis (of cyclodextrins and their complexes).
Learn more from Dani’s creation and get in touch if you have a problem to chat about in this field.
We are pleased to announce that Carbohyde Zrt. has received funding under the Economic Development and Innovation Operational Program Plus, specifically through the GINOP_PLUSZ-2.1.3-24 call for proposals! 🚀 The project aims to introduce innovations in the company’s manufacturing and marketing processes. As part of this, a digitally supported, partially automated manufacturing model will be implemented, increasing capacity utilization and reducing external dependencies. Additionally, a new data-driven marketing model will be developed, enabling scalable and measurable campaigns.
As part of the project, Carbohyde Zrt. has received a grant of 40,724,066 HUF. The project started on December 1, 2025, with a planned completion date of November 30, 2026.
The development is co-financed by the European Union and the Hungarian state, contributing to the increased competitiveness of the Hungarian economy. 🌍💡
Let’s Build Hungary Together! 🇭🇺
Kisléptékű innovációs beruházás a Carbohyde Zrt.-nél
Örömmel értesítjük partnereinket, hogy a Carbohyde Zrt. elnyerte a Gazdaságfejlesztési és Innovációs Operatív Program Plusz keretében meghirdetett GINOP_PLUSZ-2.1.3-24 azonosító számú pályázat támogatását! 🚀 A projekt célja, hogy a vállalkozás gyártási és marketingfolyamatai között innovációkat vezessen be. Ennek részeként digitálisan támogatott, részben automatizált gyártási modell kerül bevezetésre, amely növeli a kapacitáskihasználást és csökkenti a külső függőséget. Ezen kívül egy új, adatvezérelt marketingmodell is kialakításra kerül, amely skálázható, mérhető kampányokat tesz lehetővé.
A projekt keretében a Carbohyde Zrt. 40 724 066 Ft támogatásban részesült. A projekt kezdete 2025. december 1., a befejezés tervezett dátuma pedig 2026. november 30.
A fejlesztés az Európai Unió és a magyar állam társfinanszírozásával valósul meg, és hozzájárul a magyar gazdaság versenyképességének növeléséhez. 🌍💡
Építsük együtt Magyarországot! 🇭🇺
I love to feel proud.
Which is exactly what it felt to read the latest patent of Clinch Biosciences / Motorpharma Ltd.
Not because they use cyclodextrin (okay, a little bit of that too – HPBCD). For two main reasons:
1. The pioneering discovery and development work they are doing to treat muscle-related diseases and symptoms with myosin inhibitors. They are determined, passionate, persistent, and unique.
2. They are the exception. They showed us that it is possible to start and carry out innovative NCE development in Hungary, to form a pharma company around i,t and lead it to success.
I strongly believe their example will resonate in many other Hungarian companies and inspire us to dream big and live those dreams.
Thank you for being a model!
And for the rest, check out their website, certainly worth it. Patent in comment.
WO2026020167 INHIBITORS OF SMOOTH MUSCLE MYOSINS AND USES THEREOF
We are happy and proud to finally announce that CarboHyde won a 2024-1.2.7-EUROSTARS-2025-00007 grant and shall receive ~190,000k Eur to develop a novel cyclodextrin-based Alzheimer asset.
The development will be done in a consortium involving Renatus and Ajou University.
The novel mechanism of action focuses on cholesterol modulation in this neurodegenerative disease and will aim to complete most IND-enabling preclinical studies so that regulatory filings and clinical studies can begin shortly.
Join CarboHyde for the 11th edition of its flagship Masterclass series—an expert-led deep dive into parenteral cyclodextrin applications.
Event registration:
CarboHyde’s Cyclodextrin Masterclass XI – Parenteral Applications of Cyclodextrins – CarboHyde
This advanced, practice-oriented session explores how cyclodextrins enable safe, effective injectable formulations across small molecules and biologics, including protein therapeutics and vaccines.
The Masterclass blends scientific fundamentals, hands-on formulation strategy, and real-world case studies, addressing both opportunities and limitations while highlighting emerging directions in the field.
What You’ll Learn
Parenteral-grade cyclodextrins: selection criteria, quality attributes, and regulatory expectations
Formulation development & optimization: solubility enhancement, stability, compatibility, and excipient interactions
Biologics-focused insights: protein stabilization, aggregation control, vaccine formulation considerations
Small-molecule injectables: complexation strategies, safety margins, and performance trade-offs
Case studies: successes, pitfalls, and decision frameworks from development to scale-up
Limitations & risk management: toxicity thresholds, dosing constraints, and formulation boundaries
What’s next: novel derivatives, new indications, and innovation pathways
Who Should Attend?
This Masterclass is designed for professionals working in or transitioning to parenteral drug development, including:
Formulation Scientists & R&D Leaders (small molecules and biologics)
CMC, Pharmaceutical Development & Technical Operations Teams
Vaccine Developers & Protein Scientists
Drug Delivery & Enabling Technology Specialists
Regulatory Affairs & Quality Professionals
Project Managers & Decision-Makers evaluating injectable formulation strategies
Why You’ll Benefit
Practical, decision-ready knowledge: Move beyond theory to actionable formulation strategies
Cross-modality perspective: Understand how cyclodextrins behave differently with proteins, vaccines, and small molecules
Risk-aware development: Learn where cyclodextrins add value—and where they may not
Accelerated development timelines: Apply proven approaches to reduce iteration cycles
Future-proof insights: Stay ahead of regulatory, technological, and clinical trends
Format & Experience
Live, expert-led online session
Structured learning + applied examples
Interactive discussion and Q&A
Comprehensive takeaways you can apply immediately in development programs
Key Topics at a Glance
Parenteral excipient requirements
Cyclodextrin–API and cyclodextrin–protein interactions
Stability, safety, and scalability
Clinical and commercial considerations
Innovation beyond current standards
Who It’s For (In One Line)
If you develop, evaluate, or make decisions about injectable formulations—from early R&D to late-stage programs—this Masterclass is built for you.
We are the proudest, when students we mentor flourish and grow.
Fahad Khan Tareen, PhD spent a short time this year at CarboHyde, so we dont take the merits for his excellent science, but hope the insights we gave can contibute to his career.
Congratulations on your PhD!
We wish you the best, and dont dare to move away from cyclodextrins 🙂
We are happy and proud to finally announce that CarboHyde won a 2024-1.2.7-EUROSTARS-2025-00007 grant and shall receive ~190,000k Eur to develop a novel cyclodextrin-based Alzheimer asset.
The development will be done in a consortium involving Renatus and Ajou University.
The novel mechanism of action focuses on cholesterol modulation in this neurodegenerative disease and will aim to complete most IND enabling preclinical studies so that regulatory filings and clinical studies can begin shortly.
This year’s journey of co-authoring multiple research papers (8), we feel proud and humbled by the collective effort and trust from our collaborators.
This effort has also been recognized when Milo Malanga PhD received the 1st Thorseinn Loftsson award for cyclodextrin research recently.
Our work — from advancing molecular understanding of cyclodextrin host–guest systems and enantioselective complexation, to proposing a clearer nomenclature for modified cyclodextrins, and exploring innovative drug delivery strategies — contributes to practical building blocks for pharmaceutical science.
Cyclodextrins and their derivatives remain versatile tools in enhancing drug solubility, stability, and delivery performance, and clearer frameworks and analytical insights help accelerate their adoption in real-world drug development.
Science is a shared effort — these studies represent many minds thinking together to address complex challenges in drug formulation and molecular design.
We are thankful to our co-authors, reviewers, and supporting institutions for making this possible.
Looking forward to what we’ll discover next!
Ep50: Speaking Up in Science with Tamas Sohajda | Podcasts
Recently I had the chance to sit down with Louise Jefferies on her podcast Speaking up in English at Work for Introverts
– and it turned into one of the most honest conversations I’ve had about science, communication, and the fears many of us quietly carry.
My main message was simple:
Scientists are doing extraordinary work behind the scenes… but far too much of it never reaches the people who need it.
In the episode, we talked about something I see every day in our field:
most scientists stay silent — not because they lack expertise, but because they doubt whether their voice matters. And that silence costs the industry more than we realise.
We unpacked a lot, including
• why publishing papers is no longer enough
• how misinformation fills the void when experts hold back
• the visibility challenges introverts and multilingual scientists face
• the fear of posting, presenting, or speaking up (and why our imagined catastrophes almost never happen)
• why LinkedIn is actually one of the safest, kindest spaces to start sharing
• and how having a purpose makes fear feel a lot smaller
If there’s one thing I hope listeners take away, it’s this:
Your work can influence decisions, shape policy, and move our field forward — but only if your voice is heard.
You don’t need to be louder.
You don’t need to perform.
You just need to stop hiding expertise that genuinely matters.
If you’ve ever hesitated to post, present, or speak up in a meeting, this conversation might be exactly what you need.
Moga, Punjab, India – ISF College of Pharmacy (An Autonomous College), Moga, is proud to announce that it will host the 22nd International Cyclodextrin Symposium (ICS22) from October 22-26, 2026. This marks a historic milestone as the first time this prestigious international symposium is being held in India.
The symposium, themed “Integrating Cyclodextrin and AI Techniques for Next-Generation Novel Drug Delivery Systems,” will bring together more than 500 leading scientists, researchers, academicians, and industry professionals from over 40 countries to discuss groundbreaking advances in cyclodextrin chemistry and its revolutionary applications in pharmaceutical sciences.
The symposium will cover diverse topics including:
# Cyclodextrin chemistry and characterization
# Novel drug delivery systems
# AI and machine learning in pharmaceutical formulation
# Nanotechnology applications
# Industrial perspectives and commercialization
# Regulatory aspects and quality control
# Clinical applications and case studies
